TEL-AML1

• About this biomarker
• Introduction to our products
• Why choose our products
• Main product for TEL-AML1
• Associated products
• Related publications

The chromosomal translocation t(12;21)(p13;q22) constitutes the most common translocation in B lineage childhood Acute Lymphoblastic Leukemia (ALL), accounting for 25% of childhood ALL. It is not seen in childhood Acute Myeloid Leukemia (AML), and is very rare in adult ALL.

The t(12;21) fuses the helix loop helix domain of the TEL gene to the DNA binding and transactivation domains of AML1. TEL-AML1 forms dimers and may exert a dominant negative effect on TEL.

The fusion with TEL converts AML1 from an activator to a repressor of transcription.

t(12;21) positive patients retain a good prognosis and have a more delayed time of relapse.

A large prospective study demonstrated that TEL status is a significant predictor of outcome in childhood ALL, and should be assessed for risk stratification [Rubnitz JE et al. J. Clin. Oncol. (JCO) 2008]. Some studies have reported MRD results for TEL-AML1 positive patients relying on a qualitative or semi-quantitative evaluation of the transcript level. The first large prospective study using RQ-PCR for the quantification of TEL-AML1 transcripts in order to monitor residual disease clearly demonstrated that there is rapid MRD clearance in the vast majority of patients and that slower clearance of TEL-AML1 fusion gene transcripts predicted relapse. TEL-AML1 quantification by RQ-PCR was therefore proposed to suitably complement MRD analysis for the protocol required for risk stratification in childhood ALL [Fronkova E et al. Leukemia. 2005].

TEL-AML1 FusionQuant® technology uses Real-Time Quantitative RQ-PCR to quantify the expression level of specific TEL-AML1 fusion gene transcripts relative to ABL control gene.

Quantification of TEL-AML1  fusion gene transcripts has been standardized in the EAC (Europe Against Cancer) program [Gabert J et al. Leukemia. 2003, Beillard E et al. Leukemia. 2003], and IPSOGEN FusionQuant®  kits use this validated technology to calibrate and normalize RQ-PCR results.

Why choose TEL-AML1 FusionQuant® kit?

• EAC Standardized RQ-PCR procedures

• Calibrated and sensitive quantification of fusion gene transcript, normalized with ABL control gene (results in NCN)

• Product manufactured under ISO 13485 certification ensuring optimal quality control and full traceability

Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
J Clin Oncol. 2008
Authors: Rubnitz JE et al

TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL
Leukemia. 2005
Authors: Fronkova E et al.

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Leukemia. 2003
Authors: Gabert J et al.

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia. 2003
Authors: Beillard E et al.